Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

By K. Ray, U. Landmesser, Lawrence A Leiter, D. Kallend, R. Dufour, M. Karakas, T. Hall, R. Troquay, T. Turner, F. Visseren and 3 more. New England Journal of Medicine, 2017

869 citations recorded by the source corpus.

Subfields: Biotechnology, Surgery

View Paper: https://www.semanticscholar.org/paper/1f1a62bb4b78002fe02ac9051fa4b11c68450b83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Surgery

1. I. Graham
2. Marja-Riitta Taskinen
3. Alberico L. Catapano
4. Ulrich Laufs

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Reductions in PCSK9 and LDL-C levels were maintained for <_6 months.(338,339) No specific serious adverse events were observed.”